Harmony Biosciences (NASDAQ:HRMY) Downgraded by Wall Street Zen to Buy

Posted by Stanley Muller on Nov 1st, 2026

Wall Street Zen lowered shares of Harmony Biosciences (NASDAQ:HRMY – Free Report) from a strong-buy rating to a buy rating in a report released on Saturday,Wall Street Zen reports.

A number of other research firms also recently commented on HRMY. Truist Financial lifted their price objective on shares of Harmony Biosciences from $29.00 to $34.00 and gave the stock a “hold” rating in a report on Wednesday, August 5th. LADENBURG THALM/SH SH started coverage on shares of Harmony Biosciences in a report on Thursday, October 15th. They set a “buy” rating and a $55.00 target price on the stock. HC Wainwright restated a “buy” rating and issued a $55.00 price target on shares of Harmony Biosciences in a research report on Tuesday, October 13th. WBB Securities raised shares of Harmony Biosciences to a “hold” rating in a report on Friday, October 23rd. Finally, Wolfe Research initiated coverage on shares of Harmony Biosciences in a report on Wednesday, August 26th. They issued an “outperform” rating and a $60.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $48.00.

Get Our Latest Stock Report on Harmony Biosciences

Harmony Biosciences Price Performance

HRMY opened at $38.76 on Friday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.45 and a current ratio of 3.48. Harmony Biosciences has a 1-year low of $25.90 and a 1-year high of $43.49. The company has a 50-day moving average of $39.76 and a 200-day moving average of $34.73. The company has a market capitalization of $2.26 billion, a P/E ratio of 12.58, a PEG ratio of 0.31 and a beta of 1.01.

Harmony Biosciences (NASDAQ:HRMY – Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $1.28 EPS for the quarter, topping analysts’ consensus estimates of $0.96 by $0.32. The business had revenue of $261.28 million during the quarter, compared to the consensus estimate of $250.77 million. Harmony Biosciences had a return on equity of 20.06% and a net margin of 18.88%. The company’s revenue for the quarter was up 30.3% compared to the same quarter last year. During the same period last year, the firm earned $0.92 earnings per share. Equities analysts expect that Harmony Biosciences will post 3.73 EPS for the current fiscal year.

Insiders Place Their Bets

In other Harmony Biosciences news, insider Kumar Budur sold 35,852 shares of the firm’s stock in a transaction on Friday, September 18th. The stock was sold at an average price of $43.05, for a total value of $1,543,428.60. Following the sale, the insider directly owned 13,115 shares in the company, valued at approximately $564,600.75. This trade represents a 73.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders sold 72,406 shares of company stock valued at $3,108,520 over the last quarter. 11.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On Harmony Biosciences

Institutional investors have recently modified their holdings of the company. Farther Finance Advisors LLC increased its stake in shares of Harmony Biosciences by 166.7% during the third quarter. Farther Finance Advisors LLC now owns 816 shares of the company’s stock valued at $32,000 after acquiring an additional 510 shares during the period. Nykredit A S bought a new stake in Harmony Biosciences during the second quarter worth approximately $33,000. Signature Equity Partners LLC acquired a new stake in Harmony Biosciences in the third quarter worth approximately $37,000. Signaturefd LLC lifted its position in Harmony Biosciences by 200.0% in the third quarter. Signaturefd LLC now owns 1,686 shares of the company’s stock worth $66,000 after purchasing an additional 1,124 shares during the period. Finally, Integrated Wealth Concepts LLC acquired a new stake in Harmony Biosciences in the second quarter worth approximately $65,000. Institutional investors own 86.23% of the company’s stock.

Harmony Biosciences Company Profile

(Get Free Report)

Harmony Biosciences Holdings, Inc is a commercial-stage biopharmaceutical company focused on developing and providing therapies for patients with rare neurological disorders. The company’s activities center on conditions involving sleep-wake regulation and other central nervous system disorders where treatment options may be limited.

Harmony’s principal product is WAKIX (pitolisant), an oral, non-scheduled treatment that acts as a histamine-3 receptor antagonist/inverse agonist. In the United States, WAKIX is approved for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy and for excessive daytime sleepiness in pediatric patients aged 6 and older with narcolepsy.